v3.19.3
Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Deficit (Unaudited) - USD ($)
Preferred Stock [Member]
Series A Redeemable Convertible Preferred Stock Without Giving Effect To The Reverse Stock Split [Member]
Preferred Stock [Member]
Series B Redeemable Convertible Preferred Stock Without Giving Effect To The Reverse Stock Split [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Total
Balance (in shares) at Dec. 31, 2016 56,321,165 51,069,262 19,548,969      
Balance at Dec. 31, 2016 $ 12,734,000 $ 15,897,000 $ 20,000 $ 118,000 $ (19,733,000) $ (19,595,000)
Stock-based compensation expense       301,000   301,000
Exercise of warrants (in shares) 351,493          
Exercise of warrants $ 80,000          
Net loss         (11,561,000) (11,561,000)
Balance (in shares) at Dec. 31, 2017 2,034,548 1,833,387 701,808      
Balance at Dec. 31, 2017 $ 12,814,000 $ 15,897,000 $ 1,000 438,000 (31,294,000) (30,855,000)
Stock-based compensation expense $ 0 $ 0 $ 0 75,000 0 75,000
Net loss         (1,523,000) (1,523,000)
Balance (in shares) at Mar. 31, 2018 2,034,548 1,833,387 701,808      
Balance at Mar. 31, 2018 $ 12,814,000 $ 15,897,000 $ 1,000 513,000 (32,817,000) (32,303,000)
Balance (in shares) at Dec. 31, 2017 2,034,548 1,833,387 701,808      
Balance at Dec. 31, 2017 $ 12,814,000 $ 15,897,000 $ 1,000 438,000 (31,294,000) (30,855,000)
Net loss           (4,451,000)
Balance (in shares) at Sep. 30, 2018 2,034,548 1,833,387 701,808      
Balance at Sep. 30, 2018 $ 12,814,000 $ 15,897,000 $ 1,000 663,000 (35,744,000) (35,080,000)
Balance (in shares) at Dec. 31, 2017 2,034,548 1,833,387 701,808      
Balance at Dec. 31, 2017 $ 12,814,000 $ 15,897,000 $ 1,000 438,000 (31,294,000) (30,855,000)
Net loss           (5,985,000)
Balance (in shares) at Dec. 31, 2018 2,034,548 1,833,387 701,808      
Balance at Dec. 31, 2018 $ 12,814,000 $ 15,897,000 $ 1,000 747,000 (37,279,000) (36,531,000)
Balance (in shares) at Mar. 31, 2018 2,034,548 1,833,387 701,808      
Balance at Mar. 31, 2018 $ 12,814,000 $ 15,897,000 $ 1,000 513,000 (32,817,000) (32,303,000)
Stock-based compensation expense $ 0 $ 0 $ 0 75,000 0 75,000
Net loss         (1,422,000) (1,422,000)
Balance (in shares) at Jun. 30, 2018 2,034,548 1,833,387 701,808      
Balance at Jun. 30, 2018 $ 12,814,000 $ 15,897,000 $ 1,000 588,000 (34,239,000) (33,650,000)
Stock-based compensation expense $ 0 $ 0 $ 0 75,000 0 75,000
Net loss         (1,505,000) (1,505,000)
Balance (in shares) at Sep. 30, 2018 2,034,548 1,833,387 701,808      
Balance at Sep. 30, 2018 $ 12,814,000 $ 15,897,000 $ 1,000 663,000 (35,744,000) (35,080,000)
Balance (in shares) at Dec. 31, 2018 2,034,548 1,833,387 701,808      
Balance at Dec. 31, 2018 $ 12,814,000 $ 15,897,000 $ 1,000 747,000 (37,279,000) (36,531,000)
Stock-based compensation expense       84,000   84,000
Net loss $ 0 $ 0 $ 0 0 (2,462,000) (2,462,000)
Balance (in shares) at Mar. 31, 2019 2,034,548 1,833,387 701,808      
Balance at Mar. 31, 2019 $ 12,814,000 $ 15,897,000 $ 1,000 831,000 (39,741,000) (38,909,000)
Balance (in shares) at Dec. 31, 2018 2,034,548 1,833,387 701,808      
Balance at Dec. 31, 2018 $ 12,814,000 $ 15,897,000 $ 1,000 747,000 (37,279,000) (36,531,000)
Net loss           (9,033,000)
Balance (in shares) at Sep. 30, 2019     5,807,877      
Balance at Sep. 30, 2019     $ 6,000 35,244,000 (46,312,000) (11,062,000)
Balance (in shares) at Mar. 31, 2019 2,034,548 1,833,387 701,808      
Balance at Mar. 31, 2019 $ 12,814,000 $ 15,897,000 $ 1,000 831,000 (39,741,000) (38,909,000)
Stock-based compensation expense       84,000   84,000
Conversion of convertible notes into convertible preferred stock (in shares)   367,041        
Conversion of convertible notes into convertible preferred stock   $ 3,203,000        
Recognition of beneficial conversion feature upon conversion of convertible notes   $ 2,101,000        
Conversion of of convertible preferred stock into common stock (in shares) (2,034,548) (2,200,428) 4,234,976      
Conversion of of convertible preferred stock into common stock $ (12,814,000) $ (21,201,000) $ 4,000 34,011,000   34,015,000
Issuance of common stock for merger (in shares)     854,017      
Issuance of common stock for merger     $ 1,000 5,246,000   5,247,000
Equity issuance costs paid in stock (in shares)     17,076      
Exercise of warrants       234,000   234,000
Dividend       (5,245,000)   (5,245,000)
Spin-off of AquaMed       (1,000)   (1,000)
Net loss 0 0 $ 0 0 (4,676,000) (4,676,000)
Balance (in shares) at Jun. 30, 2019     5,807,877      
Balance at Jun. 30, 2019     $ 6,000 35,160,000 (44,417,000) (9,251,000)
Stock-based compensation expense       84,000   84,000
Net loss $ 0 $ 0 $ 0 0 (1,895,000) (1,895,000)
Balance (in shares) at Sep. 30, 2019     5,807,877      
Balance at Sep. 30, 2019     $ 6,000 $ 35,244,000 $ (46,312,000) $ (11,062,000)